Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review by Oliveira, Ana Gabriela et al.
Contents lists available at ScienceDirect
Multiple Sclerosis and Related Disorders
journal homepage: www.elsevier.com/locate/msard
Review article
Growing evidence supporting the use of mesenchymal stem cell therapies in
multiple sclerosis: A systematic review
Ana Gabriela Oliveiraa,1, Margarida Gonçalvesa,1, Helena Ferreirab,c,⁎, Nuno M. Nevesb,c,d,⁎
aMedicine School, University of Minho, Campus de Gualtar, Braga 4710-057, Portugal
b 3B's Research Group, I3B's – Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of
Excellence on Tissue Engineering and Regenerative Medicine, Avepark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, Guimarães 4805-017, Portugal
c ICVS/3B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal
d The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of Minho, Avepark, Barco, Guimarães 4805-017, Portugal






Expanded disability status scale
A B S T R A C T
Background: Multiple sclerosis (MS) typically arises in early/middle adulthood and is characterized by a pro-
gressive disability of the central nervous system (CNS). Currently approved therapies do not promote tissue
repair or stop disease progression. Emerging data demonstrate that stem cells present a great potential in re-
generative medicine and, consequently, have also been widely investigated as a potential treatment for MS.
Therefore, the aim of this study was to conduct a systematic review to inquire into the safety, tolerability, and
efficacy of mesenchymal stem cells (MSCs) therapies in MS.
Methods: Three electronic databases (Web of Science, PubMed, and Cochrane) were searched from April until
June 2019. Clinical trials or case reports with information related to the effects of MSC therapies in MS patients
were considered for this review.
Results: 10 manuscripts were selected, namely 7 uncontrolled clinical trials, 2 randomized controlled clinical
trials, and 1 case report. The overall quality of the studies was considered good. Besides minor adverse events
(AEs), it was reported one case of encephalopathy with seizures and two cases of iatrogenic meningitis, which
were not related to the treatment, but with the administration route. The analyses of the expanded disability
status scale (EDSS) in the uncontrolled clinical trials demonstrated that 48 patients improved, 39 maintained and
16 worsened their clinical condition. Regarding the randomized studies, one did not show statistically significant
variations in the mean EDSS score and in the other the mean EDSS score was statistically significantly lower for
the experimental group. The case report also showed an improvement in the EDSS score.
Conclusions: MSCs transplantation proved to be a safe and tolerable therapy. Their potential therapeutic benefits
were also validated. However, larger placebo controlled blinded clinical trials will be required to establish the
long term safety and efficacy profile of these therapies for MS. Their translation into the clinical practice can
provide a new hope for the patients of this highly debilitating disease.
1. Introduction
Multiple Sclerosis (MS) affects ca.2.5 million people worldwide and
is the main cause of chronic neurologic disability in young to middle
adulthood (onset generally between the ages of 20 and 40 years)
(Iwanowski and Losy, 2015). This disease is characterized by a pro-
gressive disability, due to gradual demyelination and variable axonal,
neuronal and astroglial injury in the brain and/or spinal cord
(Keegan and Noseworthy, 2002). MS presents mainly three different
clinical courses (Iwanowski and Losy, 2015; Thompson et al., 2018).
Relapsing-remitting (RR)MS is the most frequent course (85–90% of the
MS patients) and is characterized by exacerbations followed by full or
partial remissions (Iwanowski and Losy, 2015). In about 50–60% of
these patients, the disease evolves to secondary progressive (SP)MS,
after many years, occurring a gradual worsening of the symptoms
without remission (Giovannoni et al., 2016; Scalfari et al., 2014). Pri-
mary progressive (PP)MS affects ≈15% of the patients and is char-
acterized by a progressive dysfunction, having or not exacerbation
episodes (Ontaneda et al., 2017). Unlike PPMS, RRMS and SPMS affects
women more frequently (2.3–3.5:1) and more severely than men
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(Ontaneda et al., 2017; Ramien et al., 2016; Harbo et al., 2013).
Currently approved therapies for MS (e.g. glatiramer acetate, na-
talizumab, mitoxantrone, cladribine, and ocrelizumab) are effective to
prevent the accumulation of focal inflammatory damage and to reduce
the number of relapses, but do not promote tissue repair and are not
effective in stopping disease progression (Cohen et al., 2018; Li et al.,
2014; Comi et al., 2017). Indeed, although important advances in MS
treatment were achieved in the last decade, there is currently no cure
for this highly debilitating condition. Additionally, these medications
can present severe adverse effects, such as enhanced patient suscept-
ibility to infections and cancer. Moreover, the therapeutic options for
the more severe forms of the disease (PPMS and SPMS) are still very
limited. However, the recognition of spontaneous remyelination in MS
increased the success probability of the treatment strategies aimed at
enhancing endogenous repair (Chandran and Compston, 2005;
Prineas and Connell, 1979). Emerging evidence demonstrated that stem
cells have great potential in regenerative medicine. Indeed, they pre-
sent the potential to cure severe chronic conditions (Juric et al., 2016).
Consequently, they may provide an effective and alternative therapy to
the currently approved MS treatments (McLauchlan and
Robertson, 2018). Stem cell therapies can be used to replace damaged
or lost neuronal tissue, to replace the malfunctioning immune system,
and to provide immunosuppressive, reparative and neuroprotective
mechanisms (Shroff, 2018). The stem cells in general present ability to
ameliorate the symptoms and pathological features of MS, but their
selection should take into consideration different aspects, such as an
easy collection, immunogenicity, the possibility of oncogenic transfor-
mation, among others. There are different types of human stem cells,
such as neural stem cells (NSCs), embryonic stem cells (ESCs), induced
pluripotent stem cells (iPSCs), hematopoietic stem cells (HSCs) and
mesenchymal stem cells (MSCs). NSCs are present mainly in the sub-
granular zone of the dentate gyrus within the hippocampus and the
subventricular zone (SVZ) of the lateral ventricles (Cuascut and
Hutton, 2019). Despite promising therapeutic outcomes, one major
limitation is the limited number of endogenous NSCs that can be ob-
tained (Shroff, 2018; Cuascut and Hutton, 2019). Therefore, other types
of stem cells, such as MSCs, iPSCs, and ESCs have been used to obtain
NSCs (Shroff, 2018). The use of ESCs is controversial since they are
pluripotent stem cells derived from sacrificed embryos (Shroff, 2018).
Despite their ability to differentiate into any cell type of the body, the
transplantation of ESCs in an experimental autoimmune en-
cephalomyelitis (EAE) mice model demonstrated that the therapeutic
effect was not related to graft or host remyelination, but due to an
immunosuppressive neuroprotective mechanism (Aharonowiz et al.,
2008). A case report (Shroff, 2015) demonstrated a significant im-
provement of the symptoms in a MS patient without related adverse
Fig. 1. Flow chart of the included and excluded studies.
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effects. However, large scale studies are needed to support their efficacy
and safety. In MS, HSCs transplant intends to replace the mal-
functioning immune system after its ablation, and, consequently, the
associated efficacy can be related to either aggressive im-
munosuppression or immune system alteration (McLauchlan and
Robertson, 2018). Young patients with an inflammatory-active RRMS
are those who can benefit more from this therapy. Indeed, 70–80% of
RRMS patients after a HSCs transplant experienced a complete sup-
pression of disease activity for 4–5 years (Muraro et al., 2017). iPSCs
are generated from somatic cells and have similar potency to that of
ESCs. Mouse iPSC-derived NSCs/neural precursor cells (NPCs) im-
proved the symptoms of an EAE animal model due mainly to a neuro-
protective effect than by remyelination (Laterza et al., 2013). However,
the potential of iPSCs-derived oligodendrocyte progenitor cells in de-
myelinated axons demonstrated benefits in a non-human primate model
(Thiruvalluvan et al., 2016). Despite their potential, some caution in
their clinical use should be taken, due to the potential of immune
rejection, genetic and epigenetic abnormalities, and tumour develop-
ment (Okano et al., 2013). Adult-derived MSCs are the cell type that has
been tested most consistently in neurological diseases, given their
safety profile (Lukomska et al., 2019; Colpo et al., 2015; A Uccelli et al.,
2011). MSCs are a heterogeneous subset of stromal progenitors of
mesodermal cells with several advantages over the other stem cells,
such as easy collection, high availability, easy culture methods, low
immunogenicity allowing allotransplant, immunomodulatory ability,
no oncogenic transformation, and minor ethical concerns. They can be
isolated from various tissues, but bone marrow, and adipose tissues are
the most widely used sources of MSCs (Zheng et al., 2017;
Jorgensen and Noel, 2011). The MSCs administration in established
animal models of MS demonstrated their potential to significantly im-
prove the course of the pathology (Jiang et al., 2017; Bai et al., 2009;
Yan et al., 2018; Kassis et al., 2008). Remarkable improvements of the
MS clinical course after infusion of stem cells were obtained in clinical
trials (Keirstead, 2005; Ardeshiry Lajimi et al., 2013). Although
Table 1
Quality assessment of uncontrolled clinical trials according to the Quality Assessment Tool for Before-After Studies with No Control Group (National Heart Lung and
Blood Institute; see Appendix S1): good: ; fair: ; poor: .
Table 2
Quality assessment of randomized clinical trials using the CASP checklist (see Appendix S1): good- ; fair- .
Table 3
Quality assessment of Case Report using the checklist of BMJ Evidence-Based Medicine (see Appendix S1): good- .
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encouraging, some clinical trials indicate that the systemic injection of
MSCs has major limitations, such as poor cell survival and low dis-
tribution into the CNS (A Uccelli et al., 2011). Consequently, other
routes have been explored, such as intrathecal injections.
Due to the increasing importance of the use of stem cells in the
treatment of MS, this systematic review investigates the safety, toler-
ability, and efficacy of MSC therapies in MS based in the scientific
evidence available in the literature.
2. Materials and methods
This systematic review was conducted following the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.
2.1. Search strategy
Three electronic databases (Web of Science, PubMed and Cochrane)
were used systematically from April to June 2019. The following key-
words, Boolean operators, and combinations were used: “(Human “stem
cell” AND Multiple Sclerosis)” NOT “Embryonic” NOT “Experimental
autoimmune encephalomyelitis”.
2.2. Eligibility criteria
Experimental studies with information related to the effects of stem
cell therapies in MS patients were considered eligible. The clinical
outcomes related to efficacy measures (e.g. expanded disability status
scale -EDSS, relapse rate, whole-brain atrophy, and the number of ga-
dolinium-enhancing lesions or T2-weighted lesions in the brain and
spinal cord) and/or the adverse events (AEs) should be described. All
trial studies and case reports were considered in the evaluation. The
following records were excluded: a) reviews; b) meta-analysis; c) pro-
tocols; d) animal studies; e) other topics (studies that not include the
use of stem cell therapies in the treatment of MS patients) and f) studies
not written in English. After analyzing the full text of the eligible ar-
ticles, studies about peripheral blood stem cell transplantation and re-
cords that do not specify the stem cells type and/or origin were ex-
cluded. Only manuscripts focusing on MSC therapies were included.
After analyzing the full text of the eligible articles, we included only
manuscripts focusing on MSC therapies.
2.3. Study selection
Two reviewers independently analyzed the records initially
screened according to the inclusion and exclusion criteria. After the
agreement, full-text copies of every potentially relevant study were
obtained. This methodology allowed the simultaneous analysis of the
eligible manuscripts by the two authors. The manuscripts that fulfilled
the inclusion criteria were selected for this systematic review.
2.4. Data extraction
Information about the author names, publication date, country,
study type, time period of the study, characteristics of the participants,
inclusion and exclusion criteria and outcomes concerning AEs and EDSS
were independently collected by the two researchers in the original
reports. The assessment of the improvement or worsening of MS pa-
tients is based on a set of clinical parameters (Section 2.2), but the EDSS
score was the unique outcome parameter reported in all the selected
papers, being consequently selected to evaluate the efficacy outcomes.
Data treatment consisted in the calculation of means and percentages.
2.5. Quality appraisal
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using the Quality Assessment Tool for Before-After Studies with No
Control Group (National Heart Lung and Blood Institute). For rando-
mized-controlled trials, the methodological quality assessment was di-
rectly retrieved from the Critical Appraisal Skills Programmer (CASP)
checklist. The checklist of BMJ Evidence-Based Medicine, except the
fifth question, since did not fit our study, was used for the case report.
3. Results
3.1. Design and samples
In this study, 863 references were initially identified through da-
tabase searching. In the first screening, 528 manuscripts were excluded
(reviews, meta-analysis, protocols and other non-primary research ar-
ticles). By further reading the titles and abstracts of the remaining 335
articles, 300 were excluded by the following criteria: other topics, an-
imal studies or studies not written in English (Section 2.2). The full texts
of the remaining 35 eligible articles were further analyzed. Finally, 10
studies were selected, due to their focus on the study of safety and/or
efficacy of MSC therapies in MS. The flowchart of the review process is
present in Fig. 1.
3.2. Quality appraisal
Tables 1–3 (see Appendix S1) present the results of the quality
evaluation performed for the methodology of the uncontrolled clinical
trials, randomized controlled clinical trials and a case report, respec-
tively. Considering the results obtained and the number of red and
green classifications, the quality of the methodology used in the un-
controlled clinical trial studies was considered good in three, fair in one
and poor in the remaining three cases (Table 1). Both randomized
clinical trials (Table 2) and the case report (Table 3) presented a good
quality of the methodology used in their studies. However, one of the
randomized clinical trials as a higher number of green classifications,
and consequently, was considered of very good quality.
3.3. Studies characteristics
Ten studies were selected for this systematic review and their main
characteristics are present in Table 4. Nine of the studies were clinical
trials and one was a case report. In the clinical trials group, two are
controlled and randomized. Moreover, one of those is triple blinded.
The phases of clinical trials varied: five are phase I clinical trials, two
are phase II clinical trials and two are phase I/II clinical trials. Despite
all studies are based on the treatment of MS with MSCs, different tissue
sources and routes of administration were used (Table 4). Seven of the
studies used autologous bone marrow-derived (B)MSCs, one used au-
tologous adipose-derived (A)MSCs, one used healthy human donor
umbilical cord (UC)MSCs and the other used cells-derived from both
autologous bone marrow and umbilical cord donors. Regarding their
administration, three routes were used (Table 4). Three of the studies
used an intravenous (IV) infusion, five administered the cells by the
intrathecal route, one used both approaches and one used the in-
trathecal and intracisternal injections. The time period of follow up of
the studies also varied (Table 4). The mean time period for all studies
was about 24 months, being the maximum and minimum of follow up
of 7.4 years and 6 months, respectively. Table S1 presents the inclusion
and exclusion criteria of the selected studies.
3.4. Population description
161 participants were enrolled in the selected studies, being 52 male
and 109 female. Their ages varied in the interval between 22 and 65
years. The clinical conditions of the participants were evaluated using
the EDSS scale before study beginning. Different scores were obtained,
being the minimum and maximum of 3.5 and 9, respectively. Although
the MS clinical course was not described in one of the included studies
(Karussis et al., 2010), the other studies involved 109 SPMS, 27 RRMS,
and 10 PPMS patients. Table 5 presents the main characteristics of the
patients enrolled in the selected studies.
3.5. Main outcomes
The outcomes obtained in the different studies were variable. In this
systematic review, we focused on two, namely: the AEs of the therapy
and the changes in the EDSS score (Table 6).
The analyzed studies reported some AEs (Table 6). The studies in
which intrathecal injection was the selected administration route re-
ported frequent headaches and low-grade fever. One case of en-
cephalopathy with seizure and two cases of iatrogenic meningitis were
also reported. For the studies that used IV infusion for cells adminis-
tration, the most typical adverse effects reported were urinary tract
infections and respiratory infections.
The analyses of the EDSS score (Table 6) were followed by their
correlation with the clinical course of MS, the origin of MSCs and the
sex of the patients. The randomized study of Fernandez et al. (2018)
included 30 patients with SPMS, which were treated with AMSCs. The
results did not show statistically significant differences in the mean
EDSS score during the study. The randomized study of Li et al. (2014)
was performed with RRMS and SPMS patients (70% RRMS patients)
and used UCMSCs for their treatment. The mean EDSS scores of the
experimental group were statistically significantly lower than those of
the control group (administration of anti-inflammatory drug and me-
thylprednisolone). Both randomized studies had 70% of female parti-
cipants.
In the uncontrolled clinical trials, five had participants with PPMS
and SPMS. Four of those studies presented the changes in the EDSS
score distributed for each clinical course. Among 42 patients with
SPMS, 4 were not followed, 11 improved, 19 did not present any im-
provement and 8 worsened the EDSS score at the end of follow up.
Analyzing the outcomes of the 6 PPMS patients, 2 improved, 1 main-
tained and 3 worsened their EDSS score. The clinical trial of Harris et al.
Table 5
Characteristics of the participants of the selected studies.
Authors, year Patients number Female number Male number Age EDSS Clinical Course
Mohyeddin Bonab et al. (2007) 10 7 3 22–40 Mean: 33 3.5 to 6.0 2 PPMS; 8 SPMS.
Karussis et al. (2010) 15 8 7 Mean: 35.3 4.0 to 8.0 eeeee
Yamout et al. (2010) 7 4 3 34–56 Mean: 42.8 4.5 to 7.5 7 SPMS.
Bonab et al. (2012) 25 19 6 23–50 Mean: 34.7 3.5 to 7.0 2 PPMS; 23 SPMS.
Hou et al. (2013) 1 0 1 25 eeeee 1 RRMS
Li et al. (2014) 23 16 7 Experimental group: 41.7 ± 5.6 Control group:
39.4 ± 3.8
4.0 to 8.0 16 RRMS; 7 SPMS.
Harris et al. (2016) 6 4 2 36–64 Mean: 43 6.5 to 9.0 2 PPMS; 4 SPMS.
Harris et al. (2018) 20 14 6 27–65 Mean: 49 3.5 to 8.5 4 PPMS; 16 SPMS.
Cohen et al. (2018) 24 16 8 Mean: 46.4 3.0 to 6.5 10 RRMS; 14 SPMS.
Fernandez et al. (2018) 30 21 9 31–61 6.0 to 9.0 30 SPMS
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(2018) included 16 participants with SPMS and 4 with PPMS. Im-
provement in the EDSS score was obtained in 8, clinical stabilization in
10 and worsened scores were observed in 2 patients. The clinical trial of
Cohen et al. (2018) was performed with 10 RRMS patients and 14 SPMS
patients. 7 of the participants presented an improvement in the EDSS
score, 4 maintained their values and 3 worsened their clinical condi-
tion. Finally, in Karussis et al. (2010) this information was not avail-
able. The percentage of females varied from 53% to 76% in the un-
controlled clinical trials. In three of these studies, the EDSS score was
described for every single patient and related to sex. Therefore, the data
obtained for 30 females and 11 males was analyzed. Regarding females
patients, 6 improved, 14 did not show differences and 10 worsened
their EDSS score. Concerning male patients, 3 improved, 4 maintained
and 1 worsened their EDSS score (3 were not followed). The other
uncontrolled clinical trial did not present sex stratification of the re-
sults. Considering all the results, it can be concluded that in the un-
controlled clinical trials: 48 patients improved, 39 maintained and 16
worsened their EDSS score throughout the study. It is also important to
highlight that all these studies used BMSCs therapies.
In the case report, a male patient with RRMS treated with both
UCMSCs and BMSCs presented a decrease in his EDSS score.
4. Discussion
This systematic review results of the growing interest and im-
portance of stem cell therapies for a seriously debilitating condition that
affects millions of patients worldwide, namely MS. Notwithstanding
different types of stem cells can be used, MSCs have been widely in-
vestigated for their multi-lineage potential, immunomodulatory effect
and limited immunogenicity, for instance (Mohyeddin Bonab et al.,
2007). Therefore, this systematic review investigated the safety, toler-
ability, and efficacy of MSCs therapies in MS.
The selected manuscripts have, overall, a good quality of the
methodology used in their studies. However, some limitations were
identified in most studies, such as their unblinded and uncontrolled
design, the small sample size and the short time period time of follow
up. Furthermore, one of the manuscripts is a case report and, conse-
quently, needs to be cautiously analyzed.
The results presented in this systematic review reinforced the safety
profile of MSCs therapies. Despite two meningitis and one transient
encephalopathy were described in the studies using intrathecal injec-
tion, the authors did not relate it with the treatment, but with the ad-
ministration route. Minor AEs reported in intrathecal injection and in
IV infusion can be considered irrelevant if the treatment proves its ef-
ficacy. However, a conclusion about safety in these studies is limited,
due to the small mean time period of follow up and sample size, raising
questions such as long term or rare AEs.
MSCs are considered non-immunogenic, however, some studies in-
dicated that repeated administration stimulates rejection. Comparing
the autologous stem cells with allogeneic from human healthy donors,
the use of autologous avoids potential concerns with immunogenic re-
actions or disease transmission (Cohen et al., 2018). The manuscripts
reviewed with human healthy donors MSCs do not report any rejection
even though multiple administrations were performed. This issue needs
to be further investigated given the small number of studies selected
using donor cells.
Despite the majority of the manuscripts were designed to establish
the safety and tolerability of MSC therapies, they also analyze their
efficacy as an outcome. Therefore, definitive conclusions cannot be
obtained for MSC therapies efficacy, but the studies reviewed show the
potential therapeutic benefits of these treatments for MS.
As previously mentioned, MS presents different clinical courses with
different responses to therapies. Nowadays, RRMS has several drugs to
target the inflammatory component of the disease with good clinical
outcomes. However, PPMS and SPMS, the more severe forms of the
disease, have very limited therapeutic options (Fernandez et al., 2018;
Harris et al., 2016). This can justify the high enrolment of PPMS and
SPMS patients in the selected studies, despite affecting a lower number
of MS patients. As RRMS usually responds better to the treatment, it
would be expected to obtain better results in the RRMS patients com-
pared to PPMS and SPMS patients. The population analyzed in this
review does not have sufficient patients with PPMS or RRMS to com-
pare the efficacy of the therapy in these different clinical courses.
Clinical trials that aim at establishing which clinical course has a better
response to MSCs treatment are needed to obtain more robust and de-
finitive conclusions.
The optimal route of MSCs administration in MS patients remains
debatable. Some studies claimed that IV infusion may be equally ef-
fective as other administration routes. Other studies declared that after
an IV infusion the number of cells available to migrate to the CNS is
reduced, since they can be trapped in the lungs, for example. Therefore,
intrathecal administration may be more effective (Cohen et al., 2018;
Karussis et al., 2010). After reviewing the selected manuscripts, it is
possible to conclude that intrathecal injection of MSCs presented
therapeutic efficacy. However, a comparison between the efficacy of IV
and intrathecal infusions cannot be drawn, since the studies adminis-
tered different types of MSCs (e.g. AMSCs and UCMSCs) and there is a
lack of studies using both intrathecal and IV injections. Moreover, one
of the selected studies that use IV infusion is a case report. To overcome
these limitations and compare these two administration routes more
effectively, blinded, controlled and randomized clinical trials with an
intrathecal injection group and an IV infusion group should be con-
ducted.
In this systematic review, as previously stated, we analyzed studies
that used different MSCs types. Despite autologous AMSCs can be ob-
tained by a less invasive procedure than bone marrow aspirations
(Fernandez et al., 2018), only one study used the adipose tissue to
obtain the cells to treat MS patients. Consequently, the absence of ro-
bust data unable draws a clear statement about the efficacy of AMSCs vs
BMSCs. This difficulty also arises for UCMSCs. However, the case report
reviewed claims that human UCMSCs may be a safe, effective and more
practical source of stem cells for the MS treatment (Hou et al., 2013).
Autologous BMSCs were the type of stem cells more prevalent in the
manuscripts considered. These cells can be readily and safely obtained
from adult bone marrow, even from patients with advanced disease
stages (Karussis et al., 2010). Nevertheless, the different types of MSCs
were not yet systematically investigated for its potency in the MS
treatment. The cohorts of patients reported in the selected manuscripts
consisted of people with moderate to the high levels of disability (EDSS
scores of 3.5–9). Therefore, the generalization of these outcomes to
patients with less severe disease stages is not possible. The diversity in
methods applied in the different studies further complicates drawing
definite conclusions. Those issues should be considered since both in-
dividually and collectively data influence the obtained conclusions.
5. Conclusions
This systematic review reinforces that MSCs transplantation is a safe
and tolerable therapy for MS patients. Moreover, the potential benefits
of MSC therapies were further consolidated on the selected manu-
scripts, however, stronger evidence in the literature is needed to con-
clude about their really efficacy and potency. Larger randomized, pla-
cebo controlled and double blinded clinical trials are required to
translate these treatments into the clinical practice to benefit millions of
patients suffering from this highly debilitating condition.
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